Abuso de Plantas Anticolinérgicas e Esquizofrenia: A Propósito de um Caso Clínico by Frias Gonçalves, Pedro et al.
2021; 7(3): 117 ‑119; 
CASE REPORT/CASO CLÍNICO
Anticholinergic Plant Misuse and Schizophrenia: Regarding a Case Report
Abuso de Plantas Anticolinérgicas e Esquizofrenia: A Propósito de um Caso 
Clínico
D PEDRO FRIAS GONÇALVES*1, D LILIANA CASTRO2, D JORGE MOTA3, D RAQUEL ESCUDEIRO4
1. Médico Interno de Psiquiatria no Hospital Magalhães Lemos, Porto, Portugal.
2. Médica Psiquiatra no Hospital Magalhães Lemos; Professora auxiliar convidada no ICBAS, pertencente ao CINTESIS, UP. 
3 . Médico Psiquiatria no Hospital Magalhães Lemos; Professor auxiliar convidado no ICBAS. 
4. SICAD ‑ CRI ,Porto Ocidental.
Abstract
Anticholinergic medication abuse is common in patients with schizophrenia. The recreational use of anticholinergic 
plants for their euphoria inducing and hallucinogenic properties is a rising concern in America and Eastern Europe, but 
rare in Portugal. Anticholinergic misuse poses a challenge to Psychiatrists treating patients with dual pathology, for its 
addictive potential. In managing antipsychotic medication and its side effects in this population one must have in mind 
the potential for abuse of anticholinergics.
We present a case report of a patient with schizophrenia and abuse of anticholinergic plants, after receiving biperiden to 
treat extrapyramidal symptoms. Later we discuss anticholinergic effects and potential for addiction and explore ways to 
prevent and treat drug misuse in this context.
Resumo
O abuso de medicação anticolinérgica é comum em pacientes com esquizofrenia. A utilização recreativa de plantas com 
efeito anticolinérgico pelo seu potencial alucinogénico e indutor de euforia, é um problema crescente na América e Europa 
de Leste, mas raro em Portugal. O uso inadequado de anticolinérgicos coloca um desafio no tratamento de pacientes com 
patologia dual, pelo seu potencial aditivo. A gestão da medicação antipsicótica e dos seus efeitos laterais nesta população 
tem que ter em conta o potencial de abuso de anticolinérgicos. 
Apresentamos um relato de caso de um paciente com esquizofrenia e abuso de plantas com ação anticolinérgica, após ter 
recebido biperideno para o tratamento de sintomas extrapiramidais. Posteriormente discutimos os efeitos dos anticolinér‑
gicos e o seu potencial aditivo e exploramos formas de tratar e prevenir o abuso de substâncias neste contexto.
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INTRODUCTION
Anticholinergic agents are useful in psychiatry, mainly in 
the treatment and prophylaxis of extrapyramidal symptoms 
(EPS) secondary to antipsychotic medication.1,2
Acetylcholine (Ach) is the main parasympathetic neu‑
rotransmitter, influencing circulation, motor function, 
smooth muscle activity, vision, gland secretion, alertness, 
memory and learning.3 Anticholinergics act by competitive 
inhibition of ACh synaptic receptors in both central and 
peripheral nervous systems.4 In the central nervous system 
(CNS) they stimulate the medulla and higher structures, 
eliciting euphoria, excitement, restlessness, irritability, dis‑
orientation, memory impairment, hallucinations and deliri‑
um at toxic doses (>10 mg). Severe intoxication results in 
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CNS depression symptoms and circulatory and respiratory 
collapse.5, 6
Anticholinergic misuse is rarely reported and mainly in 
patients with severe mental illness.1,6,7
Anticholinergic agents such as atropine and scopolamine 
naturally occur in several plants that are recreationally 
consumed for their hallucinogenic and euphoria ‑inducing 
properties and misuse of anticholinergic plants is a growing 
concern in America and Eastern Europe, rarely reported in 
Portugal.1,8 We present a case report of a patient diagnosed 
with paranoid schizophrenia and previous drug addiction, 
currently misusing anticholinergic plants.
CASE REPORT
A 41 ‑year ‑old male was referred to an addiction treatment 
unit in Portugal for misuse of plants Datura stramonium 
and Brugmansia suaveolens. He had history of drug ad‑
diction and paranoid schizophrenia with three psychotic 
episodes requiring hospitalization.
He started using drugs at 16 years of age, including THC, 
heroin, cocaine and sporadically LSD and MDMA. He began 
pharmacological and psychotherapeutic treatment at 26 years 
of age for drug ‑related problems, attending a rehabilitation 
clinic for six months. At this clinic, he developed acute dysto‑
nia after 10 mg of intramuscular haloperidol, which reversed 
with 10 mg (2 mL) of intramuscular biperiden.
His first psychotic episode occurred at 20 years of age, 
with severely disorganized thought and behavior and bi‑
zarre paranoid delusions. Remission was achieved after a 
week of inpatient treatment with antipsychotic medication. 
He had a similar episode at 23 years of age. Both were 
interpreted as drug induced psychosis.
In 2017, his third psychotic episode presented with per‑
secutory and hypochondriacal delusions, auditory hallu‑
cinations and mildly disorganized thought and behavior. 
After a month of inpatient antipsychotic treatment, he was 
discharged with a diagnosis of paranoid schizophrenia.
At his first appointment the patient was abstinent of illegal 
drug use for 13 years but consumed Brugmansia suaveo-
lens and Datura stramonium, which he had in his garden, 
for at least 4 years, after biperiden tablets were suspended 
for misuse. Plant species were confirmed by patient pro‑
vided photographs and samples.
Initially he ingested 3 Brugmansia or 2 Datura seeds daily, 
increasing gradually over the years to 6 or 5 seeds due to 
tolerance. 
After 24 hours without anticholinergics he developed in‑
creasing agitation, anxiety, profuse sweating, sialorrhea 
and feelings of emptiness. He reported past episodes of 
acute intoxication, disorientation, memory impairment, 
ataxia, loss of motor coordination, blurred vision and 
emotional instability coupled with hallucinations and de‑
lusions when taking higher doses.
He also complained about chronic feelings of worthless‑
ness and abulia, present since his first psychotic episode 
and worsening over the last three years with increasing 
functional impact.
Physical examination showed increased sweating and mild 
mydriasis. He was alert and cooperative, exhibiting a bizarre 
demeanor. Mood was anxious and affect flattened. Speech 
was spontaneous, circumstantial and sometimes inadequate 
although logical and coherent. He showed no signs of delu‑
sions and did not report hallucinations, auditory or otherwise. 
The patient underwent pharmacological treatment, switching 
from haloperidol 10 mg daily to quetiapine 400 mg divided 
by two daily administrations in order to reduce EPS and seda‑
tion. He received individual cognitive behavioral therapy to 
address substance addiction and was enrolled on a Day Care 
Center to promote rehabilitation. After three months of treat‑
ment he stopped using anticholinergics or other substances.
DISCUSSION
Hallucinogenic and euphoria ‑inducing plants have been 
used for millennia in different cultures for spiritual, medi‑
cal and recreational reasons.9 Datura and brugmansia spe‑
cies are among the most popular plants used recreationally 
for their psychotropic properties in America and Eastern 
Europe where intoxication is a growing concern.10 
The patient described the experience of receiving biperi‑
den to treat EPS as extremely pleasant, prompting sub‑
sequent abuse. He regularly consumed leaves or seeds of 
Brugmansia and Datura to elicit feelings of happiness, 
euphoria and hallucinations. He met ICD ‑10 criteria for 
dependence syndrome, increasing doses to maintain the 
desired effects, withdrawal symptoms and inability to re‑
duce consumption despite recognizing its negative impact 
on his health and functioning.11 He also suffered from par‑
anoid schizophrenia undergoing antipsychotic treatment. 
Negative symptoms were apparent mainly through a flat‑
tened mood and affect, circumstantial and stilted speech, 
and disproportionate interest in botanic and pharmacology.
It should be noted that chronic anticholinergic use is asso‑
ciated with cognitive decline over time that overlaps with 
cognitive symptoms of schizophrenia.12
Consumption of anticholinergic agents by schizophrenic 
patients looking for feelings of euphoria or energization has 
been previously reported. These patients show increased 
risk for anticholinergic abuse or dependence as they often 
need anticholinergic drugs to ameliorate EPS.1,13
According to the dopaminergic ‑cholinergic model of 
schizophrenia, cholinergic hyperactivity and muscarinic 
receptor downregulation relate to negative symptoms. 
By blocking muscarinic receptors, anticholinergics could 
reduce negative symptoms which helps understand the 
increased incidence of anticholinergic misuse in severely 
mentally ill patients.13,14,15 Blocking muscarinic receptors 
also inhibits dopamine reuptake and storage, enhancing 
its transmission, which may account for its euphoric and 
hallucinogenic actions, and its potential for dependence.16
This is, to our knowledge, the first reported case of anticho‑
linergic plant addiction in Portugal. The fact that it occurs in 
a schizophrenic patient highlights the need for psychiatrists 
dealing with dual pathology to recognize emerging addic‑
tive agents and consumption patterns. Optimization and 
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monitoring of anticholinergic drug prescription, educating 
patients and caregivers about the risks of anticholinergic 
addiction and misuse and favoring second generation an‑
tipsychotics to reduce EPS are strategies that can reduce 
anticholinergic addiction risk in severely mental ill patients. 
When dependence develops, it can be useful to pharma‑
cologically manage comorbid symptoms and withdrawal 
induced anxiety, and reduce anticholinergics over a 2 ‑week 
period while using adjunctive CBT.6,17 
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